Page 29 - Group Revenues News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MorphoSys AG Reports First Quarter 2021 Results Tremfya royalties of € 11.6 million Reaffirming group revenue guidance of € 150 to € 200 million Conference call and webcast (in English) tomorrow, May 6, 2021 at 2:00pm CEST (1:00pm BST/8:00am EDT) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 5, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) reports financial results for the first quarter of 2021. For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the tafasitamab backbone strategy through additional clinical studies; and expanding our pipeline, said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. While we experienced headwinds from the pandemic in the first quarter, we are cautiously optimistic that the COVID-19 impact in the U.S. will start to diminish in the second half of 2021. We are confident in the potential of Monjuvi given its broad second-line label and overall profile in the r/r DLBCL setting. We are also making

United statesUnited kingdomThomas biegiJulia neugebauerJean paul kressMyles cloustonJeanette bressiJanssen biotech incXencor incDrug administrationJanssen research developmentMorphosys us incGroup revenuesExchange commissionUs communicationsMorphosys group key figures